Company: MIRA
Filing Date: 2025-10-15
Form Type: 8-K
Source: 0001493152-25-018141
Chunk: 0

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-10-15
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events

MIRA
Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned
IND for Chronic Inflammatory Pain

Findings show oral Mira-55 fully normalized pain and significantly reduced
inflammation, supporting IND plans and reinforcing MIRA’s position in a $70 billion non-opioid pain market.

On
October 15, 2025, MIRA Pharmaceuticals, Inc. preclinical data Mira-55 oral administration of Mira-55 normalized pain and significantly reduced
inflammation injected morphine

This
study marks the first time inflammation was directly measured orally
administered Mira-55 provided superior pain normalization and direct anti-inflammatory effects

Key
observations from the study include:

  Pain                                                                                                                                      
  Inflammation                                                                                                                              
  Oral                                                                                                                                      

Reducing
inflammation is fundamental to treating pain effectively.

These
findings support the Company’s plan to pursue an Investigational New Drug (IND)

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                        MIRA                                          
  Dated:                By:                        /s/                
                        Name:                      Erez               
                        Title:                     Chief